Targeted delivery of curcumin to treat Alzheimer's disease
Official title: Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD
Funded at 3p Biotechnologies, INC. · NIH-11222978 · Data updated 2026-11-12
This study is exploring a new way to deliver curcumin, a natural compound, directly to the brain to help people with Alzheimer's disease by using tiny particles that can reach the areas of the brain affected by inflammation and plaques, aiming to improve brain function and treatment outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 3p Biotechnologies, INC. NIH-funded |
| Lab location | 1 site (Prospect, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $6,500 |
| NIH project number | 3R41AG085737-01S1 |
| Project ID | NIH-11222978 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of neuroinflammation.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research aims to develop a new method for delivering curcumin, a natural compound, directly to the brain to help treat Alzheimer's disease. By using a specialized delivery system that targets areas affected by inflammation and amyloid plaques, the researchers hope to improve the effectiveness of curcumin in reducing neuroinflammation and restoring normal brain function. The approach involves using exosomes, which are tiny particles that can cross the blood-brain barrier, to transport curcumin to the brain's cortex and hippocampus. This innovative method could enhance the treatment of Alzheimer's and potentially other neuroinflammatory diseases.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, improving the quality of life for patients.
How similar studies have gone: While the use of targeted delivery systems for neurodegenerative diseases is a growing field, this specific approach using curcumin and exosomes is relatively novel and has not been extensively tested.
Where this research is happening
-
3p Biotechnologies, INC.
Prospect, United States Active
Researchers
- Principal investigator: Gupta, Ramesh C — 3p Biotechnologies, INC.
- Study coordinator: Gupta, Ramesh C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.